Key Sessions
Brian Recchione
KEYNOTE: Success with External Manufacturing
ImmunoGen
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference Day 3 (Exhibit Hall Open 9:45am-1:30pm) - PT (Pacific Time, GMT-08:00)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Formats
Main Conference Day 3 (Exhibit Hall Open 9:45am-1:30pm) - PT (Pacific Time, GMT-08:00)
search
Streams
Clear
Formats
Showing 1 of 1 Streams
Cell Line Development & Engineering
8:25am - 8:30am
Chairperson's Opening Remarks
8:30am - 9:00am
Development of Stable Pool Expression Platform in HEK293 Cells
- Yi Liu - Scientist III and Team Lead, Cell Line Development Vaccine Production Program, VRC/NIAID/NIH
9:00am - 9:30am
Next Generation Cell Line Analytics
- YenRu Pan - Senior Research Scientist II (Associate Director), Gilead Sciences
9:30am - 10:00am
C.STATION: End-to-end automation for generating stable cell lines for the development of advanced therapeutics
- Erica Squires - Western Regional Manager, BioPharma, CYTENA GmbH
Showing 1 of 1 Streams
Cell Line Development & Engineering
11:00am - 12:00pm
Panel Discussion: How many cell lines should you have?
- Sampath Kumar - Senior Director and Head of Cell Line Development, Biologics Process Development, Takeda Pharmaceuticals
- Saurabh Sen - Associate Director, Cell Line Development, Genomic Medicine Unit CMC, Sanofi
- Ken Lee - Director, Bioprocess Technologies and Engineering, BioPharmaceuticals Development, R&D, AstraZeneca
- Lina Chakrabarti - Associate Director, R & D, Astrazeneca
12:00pm - 12:30pm
Scientific Track Presentation by Advanced Instruments
Showing 1 of 1 Streams
Cell Line Development & Engineering
1:30pm - 2:00pm
Rapid development of trimeric SARS-CoV-2 spike-based vaccine candidates using stable CHO pools
- Yves Durocher, PhD - Section Head, Mammalian Cell Expression - NRC Human Health Therapeutics Research Center, National Research Council Canada
2:00pm - 2:30pm
Simplifying CHO cell line generation with high probability of monoclonality using microfluidics dispensing as an alternative to FACS
- Lina Chakrabarti - Associate Director, R & D, Astrazeneca
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear
Formats